- Home
- UDMY vs XNCR Comparison
UDMY vs XNCR Comparison
Compare UDMY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UDMY | XNCR |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UDMY | XNCR |
|---|---|---|
| Price | $5.80 | $15.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $9.00 | ★ $22.78 |
| AVG Volume (30 Days) | ★ 4.1M | 838.7K |
| Earning Date | 02-12-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $795,801,000.00 | $150,132,000.00 |
| Revenue This Year | $2.34 | $18.81 |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.53 | ★ 38.16 |
| 52 Week Low | $4.86 | $6.92 |
| 52 Week High | $10.61 | $24.94 |
Technical Indicators
Market Signals| Indicator | UDMY | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 45.09 |
| Support Level | $5.80 | $16.44 |
| Resistance Level | $7.16 | $16.17 |
| Average True Range (ATR) | 0.32 | 0.92 |
| MACD | 0.10 | -0.30 |
| Stochastic Oscillator | 34.95 | 5.76 |
Price Performance
Historical ComparisonAbout UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.